We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
- Authors
Buse, John B; Drucker, Daniel J; Taylor, Kristin L; Kim, Terri; Walsh, Brandon; Hu, Hao; Wilhelm, Ken; Trautmann, Michael; Shen, Larry Z; Porter, Lisa E; DURATION-1 Study Group
- Abstract
In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide QW; 2 mg) was compared with exenatide BID in 295 patients with type 2 diabetes. We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
- Publication
Diabetes care, 2010, Vol 33, Issue 6, p1255
- ISSN
1935-5548
- Publication type
Journal Article
- DOI
10.2337/dc09-1914